M
Michael D. Pierschbacher
Researcher at National Foundation for Cancer Research
Publications - 93
Citations - 24291
Michael D. Pierschbacher is an academic researcher from National Foundation for Cancer Research. The author has contributed to research in topics: Fibronectin & Vitronectin. The author has an hindex of 50, co-authored 93 publications receiving 23883 citations. Previous affiliations of Michael D. Pierschbacher include Integra Telecom & Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
New perspectives in cell adhesion : RGD and integrins
TL;DR: Together, the adhesion proteins and their receptors constitute a versatile recognition system providing cells with anchorage, traction for migration, and signals for polarity, position, differentiation, and possibly growth.
Journal ArticleDOI
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
TL;DR: The ability of fibronectin to bind cells can be accounted for by the tetrapeptide L-arginyl-glycyl- L-aspartyl-L-serine, a sequence which is part of the cell attachment domain of fibronsectin and present in at least five other proteins.
Journal ArticleDOI
Arg-Gly-Asp: a versatile cell recognition signal.
TL;DR: The RGD sequence as a basic unit of a widespread cellular recognition system is established and the same peptides also inhibit the attachment of fibroblasts to a number of other proteins, including vitronectin.
Journal ArticleDOI
Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor
TL;DR: Affinity chromatography on wheat germ agglutinin-Sepharose showed that the 140 kd protein is a glycoprotein and, in combination with the fibronectin fragment chromatography, gave highly enriched preparations of the 140Kd protein.
Journal ArticleDOI
Natural inhibitor of transforming growth factor-|[beta]| protects against scarring in experimental kidney disease
Wayne A. Border,Nancy A. Noble,Tatsuo Yamamoto,John R. Harper,Yu Yamaguchi,Michael D. Pierschbacher,Erkki Ruoslahti +6 more
TL;DR: It is reported here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming the hypothesis that decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-β.